FDA Approves ViiV Healthcare's Epivir
Epivir is an antiviral medication that prevents human immunodeficiency virus (HIV) cells from multiplying in your body.
The Epivir brand of lamivudine is used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). Lamivudine is not a cure for HIV or AIDS. The Epivir-HBV brand of lamivudine is used to treat chronic hepatitis B. Epivir-HBV should not be used in people who are infected with both hepatitis B and HIV. It works by blocking the ability of the hepatitis B virus to multiply and infect new liver cells.
Epivir is an HIV medication. It is in a category of HIV medications called nucleoside reverse transcriptase inhibitors (NRTIs). Epivir prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
Epivir, manufactured by ViiV Healthcare, was approved for the treatment of HIV by the U.S. Food and Drug Administration (FDA) in 1995.
Epivir is available in pharmacies as a single drug, which is always combined with other HIV drugs, or in three combination tablets: Combivir (Retrovir and Epivir), Trizivir (Retrovir, Ziagen, and Epivir), or Epzicom (Ziagen and Epivir).
Epivir is also approved for the treatment of chronic hepatitis B infection (Epivir HBV). The Epivir dose normally used to treat hepatitis B is one 100mg tablet once a day. The dose used to treat HIV is one 300mg tablet once a day, or one 150mg tablet every 12 hours. If you are infected with both HIV and hepatitis B, it is important that you take the dose used to treat HIV.
Epivir must be used in combination with other HIV drugs.
EPIVIR in combination with other antiretroviral agents is indicated for the treatment of HIV infection. The use of EPIVIR is based on the results of clinical studies in HIV-infected patients in combination regimens with other antiretroviral agents. EPIVIR does not cure HIV infection/AIDS or prevent passing HIV to others.